FINWIRES · TerminalLIVE
FINWIRES

Japan's Trade Surplus Expands in March as Exports to China, US Jump

-- Japan's trade surplus expanded to nearly 667 billion yen in March from 529.8 billion yen a year earlier as exports outpaced imports, data from the Ministry of Finance on Wednesday showed.

Exports during the month climbed 11.7% to 11.003 trillion yen from 9.852 trillion yen, after shipments to its two largest trading partners, China and the US, rose 17.7% and 3.4%, respectively.

This March export reading is triple that of the export growth of 4% the month prior.

Exports to the Middle East plunged 45.9% while imports fell 10.7%, as the Iran war effectively shut the Strait of Hormuz, a vital waterway for Japan's oil imports from the region.

Overall imports, meanwhile, grew 10.9% on year to 10.336 trillion yen from 9.322 trillion yen, boosted mostly by imports from Asian nations.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062